KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kyverna Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.83+0.16 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
60.8%
38M of 62M shares
Institutional holders
120
31 new, 21 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
2 buys · 1 sales
Net bought $1.71M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| VV Manager LLC | 4,777,060 | 11.10% | 13D (active) | Feb 12, 2024 |
| Dr. Beth C. Seidenberg ("Seidenberg") | 4,657,257 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Gilead Sciences, Inc. | 4,126,119 | 9.00% | 13G (passive) | Feb 12, 2024 |
| Michael P. Rubin | 3,466,826 | 6.10% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,103,757 | 5.10% | 13G (passive) | Jun 30, 2026 |
| GordonMD Global Investments GP LLC | 3,058,485 | 7.00% | 13G (passive) | Nov 13, 2025 |
| JPMorgan Chase & Co. | 2,380,021 | 5.50% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KYTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 4,244,818 | 6.86% | $37.82M | – | 18.30% |
| Gilead Sciences, Inc. | 4,126,119 | 6.67% | $36.76M | – | 2.23% |
| BlackRock, Inc. | 3,134,807 | 5.07% | $27.93M | +2,257,729 | 0.00% |
| Bain Capital Life Sciences Investors, LLC | 2,885,000 | 4.67% | $25.71M | −225,000 | 1.53% |
| AIGH Capital Management LLC | 2,795,797 | 4.52% | $24.91M | +795,797 | 1.57% |
| Deerfield Management Company, L.P. (Series C) | 2,000,000 | 3.23% | $17.82M | – | 0.19% |
| Vanguard Capital Management LLC | 1,897,451 | 3.07% | $16.91M | +114,109 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,186,023 | 1.92% | $10.57K | −369,264 | 0.00% |
| Geode Capital Management, LLC | 1,049,430 | 1.70% | $9.35M | +625,604 | 0.00% |
| Insight Holdings Group, LLC | 989,054 | 1.60% | $8.81M | – | 0.67% |
| Morgan Stanley | 982,307 | 1.59% | $8.75M | +5,018 | 0.00% |
| State Street Corp | 982,233 | 1.59% | $8.75M | +843,933 | 0.00% |
| Propel Bio Management, LLC | 883,198 | 1.43% | $7.87M | +238,777 | 4.12% |
| Woodline Partners LP | 845,325 | 1.37% | $7.53M | – | 0.02% |
| Millennium Management LLC | 639,780 | 1.03% | $5.70M | −365,728 | 0.00% |
| Mbb Public Markets I LLC | 614,477 | 0.99% | $5.47M | – | 0.59% |
| Adage Capital Partners Gp, L.L.C. | 500,000 | 0.81% | $4.46M | – | 0.01% |
| D. E. Shaw & Co., Inc. | 469,346 | 0.76% | $4.18M | −252,235 | 0.00% |
| Wells Fargo & Company/Mn | 373,009 | 0.60% | $3.32M | +258,610 | 0.00% |
| UBS Group AG | 365,574 | 0.59% | $3.26M | −84,176 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 38M | 60.8% | 31 / 36 | 28 / 21 | 8M | 5M |
| Q1 2026 | 111 | 35M | 56.3% | 27 / 31 | 35 / 14 | 7M | 4M |
| Q4 2025 | 99 | 34M | 55.2% | 36 / 29 | 21 / 9 | 18M | 2M |
| Q3 2025 | 75 | 23M | 36.7% | 10 / 18 | 29 / 14 | 1M | 2M |
| Q2 2025 | 79 | 23M | 37.5% | 16 / 29 | 24 / 24 | 2M | 5M |
| Q1 2025 | 87 | 26M | 41.7% | 15 / 26 | 25 / 15 | 2M | 5M |
| Q4 2024 | 88 | 29M | 46.7% | 23 / 32 | 14 / 28 | 8M | 6M |
| Q3 2024 | 94 | 31M | 49.4% | 28 / 24 | 22 / 21 | 4M | 6M |
| Q2 2024 | 88 | 34M | 55.0% | 28 / 33 | 13 / 30 | 10M | 8M |
| Q1 2024 | 90 | 32M | 51.4% | 90 / 0 | 0 / 0 | 32M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KYTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,403,697 | 2.27% | $12.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,073,618 | 1.74% | $9.57M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 856,798 | 1.39% | $7.63M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 458,351 | 0.74% | $3.35M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 448,147 | 0.72% | $3.99M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 352,088 | 0.57% | $3.14M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 266,211 | 0.43% | $2.37M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 260,625 | 0.42% | $2.32M | 0.08% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 183,789 | 0.30% | $1.57M | 0.00% | May 31, 2026 |
| Simplify Propel Opportunities ETF | 182,603 | 0.30% | $1.63M | 2.11% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 177,936 | 0.29% | $1.30M | 0.00% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 167,964 | 0.27% | $1.43M | 0.01% | May 31, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 166,182 | 0.27% | $1.42M | 0.34% | May 31, 2026 |
| iShares Micro-Cap ETF | 139,400 | 0.23% | $1.24M | 0.08% | Jun 30, 2026 |
| Ultra-Small Company Fund | 112,000 | 0.18% | $997.92K | 1.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christi Shaw | Executive Chairperson, Director | 66,741 | 0.11% | May 29, 2026 |
| Warner Weston Biddle | Chief Executive Officer, Director | 58,000 | 0.09% | Mar 17, 2026 |
| Gregory S. Martini | Chief Financial Officer | – | – | May 20, 2026 |
| Nadia Dac | Chief Commercial Officer | – | – | May 6, 2026 |
| Marc Grasso | Chief Financial Officer | 10,000 | 0.02% | Mar 17, 2026 |
| Naji Gehchan | See Remarks | 18,000 | 0.03% | Mar 17, 2026 |
| Mayobanex Pujols | Chief Technology Officer | – | – | Feb 11, 2026 |
| Karen Marie Walker | Chief Technology Officer | 22,636 | 0.04% | Dec 17, 2025 |
| Ryan Alexander Jones | Chief Financial Officer | 55,950 | 0.09% | Apr 15, 2025 |
| Fred E. Cohen | Director | 4,545,651 | 7.35% | May 29, 2026 |
| Beth C. Seidenberg | Director | 891,044 | 1.44% | May 29, 2026 |
| Ian T. Clark | Director | 21,727 | 0.04% | May 29, 2026 |
| Mert Aktar | Director | 21,727 | 0.04% | May 29, 2026 |
| Andrew Craig Miller | Director | 11,006 | 0.02% | Mar 4, 2026 |
| Sravan Kumar Emany | Director | 11,006 | 0.02% | Feb 26, 2026 |
| Daniel K. Spiegelman | Director | 16,634 | 0.03% | Jun 2, 2025 |
| Westlake BioPartners GP I, LLC | 10% owner | 735,984 | 1.19% | Dec 22, 2025 |
| Westlake BioPartners Opportunity GP I, LLC | 10% owner | – | – | Dec 22, 2025 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | 869,317 | 1.41% | Dec 22, 2025 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | – | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christi Shaw Executive Chairperson, Director | May 27, 2026 | Tax withholding | −4,194 | $8.59 | $36.03K | 66,741 |
| Beth C. Seidenberg Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Ian T. Clark Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Fred E. Cohen Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Mert Aktar Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Marc Grasso Chief Financial Officer | Mar 13, 2026 | Award | +10,000 | – | – | 10,000 |
| Naji Gehchan See Remarks | Mar 13, 2026 | Award | +18,000 | – | – | 18,000 |
| Warner Weston Biddle Chief Executive Officer, Director | Mar 13, 2026 | Award | +58,000 | – | – | 58,000 |
| Andrew Craig Miller Director | Feb 24, 2026 | Award | +11,006 | – | – | 11,006 |
| Sravan Kumar Emany Director | Feb 24, 2026 | Award | +11,006 | – | – | 11,006 |
| Christi Shaw Executive Chairperson, Director | Jan 12, 2026 | Award | +24,301 | – | – | 70,935 |
| Christi Shaw Executive Chairperson, Director | Jan 12, 2026 | Award | +30,000 | – | – | 46,634 |
| Westlake BioPartners Opportunity Fund I, L.P. 10% owner | Dec 18, 2025 | Buy | +133,333 | $7.50 | $1,000.00K | 869,317 |
| Beth C. Seidenberg Director | Dec 18, 2025 | Buy | +133,333 | $7.50 | $1,000.00K | 869,317 |
| Karen Marie Walker Chief Technology Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −23,998 | $12.20 | $292.78K | 22,636 |
| Karen Marie Walker Chief Technology Officer | Dec 15, 2025 | Option exercise | +23,998 | $4.83 | $115.91K | 46,634 |
| Fred E. Cohen Director, 10% owner | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Daniel K. Spiegelman Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Ian T. Clark Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Beth C. Seidenberg Director, 10% owner | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Christi Shaw Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Mert Aktar Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Karen Marie Walker Chief Technology Officer | Apr 11, 2025 | Award | +13,000 | – | – | 22,636 |
| Ryan Alexander Jones Chief Financial Officer | Apr 11, 2025 | Award | +12,000 | – | – | 55,950 |
| Karen Marie Walker Chief Technology Officer | Jun 6, 2024 | Option exercise | +9,636 | $4.42 | $42.59K | 9,636 |
| Ryan Alexander Jones Chief Financial Officer | May 28, 2024 | Option exercise | +7,146 | $0.73 | $5.22K | 43,950 |
| Ryan Alexander Jones Chief Financial Officer | May 28, 2024 | Option exercise | +10,870 | $0.73 | $7.94K | 36,804 |
| Westlake BioPartners GP I, LLC 10% owner | Feb 12, 2024 | Conversion | +735,984 | – | – | 735,984 |
| Westlake BioPartners GP I, LLC 10% owner | Feb 12, 2024 | Conversion | +3,787,940 | – | – | 3,787,940 |
| Bain Capital Life Sciences Fund III, L.P. 10% owner | Feb 12, 2024 | Buy | +450,000 | $22.00 | $9.90M | 3,163,868 |
| Bain Capital Life Sciences Fund III, L.P. 10% owner | Feb 12, 2024 | Conversion | +2,713,868 | – | – | 2,713,868 |
| Beth C. Seidenberg Director, 10% owner | Feb 12, 2024 | Conversion | +735,984 | – | – | 735,984 |
| Beth C. Seidenberg Director, 10% owner | Feb 12, 2024 | Conversion | +3,787,940 | – | – | 3,787,940 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Buy | +583 | $22.00 | $12.83K | 583 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Buy | +252,553 | $22.00 | $5.56M | 252,553 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Conversion | +4,523,924 | – | – | 4,523,924 |
| Fred E. Cohen Director, 10% owner | Feb 12, 2024 | Conversion | +4,523,924 | – | – | 4,523,924 |
| Gilead Sciences, Inc. 10% owner | Feb 12, 2024 | Buy | +910,000 | $22.00 | $20.02M | 4,126,119 |
| Gilead Sciences, Inc. 10% owner | Feb 12, 2024 | Conversion | +3,216,119 | – | – | 3,216,119 |
| Northpond Ventures III GP, LLC – | Feb 12, 2024 | Conversion | +2,805,426 | – | – | 2,805,426 |
| Northpond Ventures III GP, LLC – | Feb 12, 2024 | Buy | +450,000 | $22.00 | $9.90M | 450,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Walker Karen Officer | Apr 17, 2026 | 10,000 | $95.30K | Apr 17, 2026 | Exercise of Stock Options |
| Walker Karen Officer | Apr 14, 2026 | 2,459 | $23.34K | Apr 14, 2026 | Restricted Stock Units |
| Spiegelman Daniel Director | Apr 7, 2026 | 17,578 | $162.64K | Apr 7, 2026 | Stock Option Exercise |
| Spiegelman Daniel Director | Mar 31, 2026 | 16,634 | $140.40K | Mar 31, 2026 | Restricted Stock |
| Walker Karen Officer | Dec 15, 2025 | 23,998 | $210.70K | Dec 15, 2025 | Exercise of Stock Options |